ATLANTA, GA (Globe Newswire – November 3, 2025) — Holzer & Holzer, LLC is investigating whether uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) complied with federal securities laws. On November 3, 2025, uniQure disclosed it had a pre-Biologics License Application (“BLA”) meeting with the U.S. Food and Drug Administration (“FDA”) and that based on the meeting, “uniQure believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission.”  Following this news, the price of the Company’s stock dropped.

If you purchased uniQure stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/uniqure/ to discuss your legal rights.